Who
John Greene
Director
Company insider
Files Form 4 as: Director, CRISPR Therapeutics AG; CVP & Chief Financial Officer, Northrop Grumman; EVP, Chief Financial Officer, Discover Financial Services; EVP, CFO and Treasurer, Bioverativ; Chief Financial Officer, Willis Towers Watson Public Limited.
In numbers
- Trades disclosed
- 61
- Buys
- 2
- Sells
- 2
- Bought
- $563K
- Sold
- $4.3M
- Companies
- 5
- Companies where not an officer
- 1
- First trade
- 11 Aug 2014
- Last trade
- 5 Jun 2026
- Last filed
- 9 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 9 Jun 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | NOC Northrop Grummanoption or derivative · Aerospace & Defense | SEC FORM 4 Code A | —4,981 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | NOC Northrop Grummanoption or derivative · Aerospace & Defense | SEC FORM 4 Code A | —5,362 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | NOC Northrop Grummanoption or derivative · Aerospace & Defense | SEC FORM 4 Code A | —4,981 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | NOC Northrop Grummanoption or derivative · Aerospace & Defense | SEC FORM 4 Code A | —5,362 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 18 May 2025filed 19 May 2025 | Discover Financial Services | SEC FORM 4 Code D | —79,943 | filing |
| 26 Feb 2025filed 28 Feb 2025 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Bought | $314K7,000 at $44.85 | filing |
| 1 Feb 2025filed 4 Feb 2025 | Discover Financial Services | SEC FORM 4 Code F | $370K1,840 at $201.09 | filing |
| 23 Jan 2025filed 27 Jan 2025 | Discover Financial Services | SEC FORM 4 Code A | —14,630 at $0.00 | filing |
| 19 Dec 2024filed 23 Dec 2024 | Discover Financial Services | SEC FORM 4 Code A | —12,109 at $0.00 | filing |
| 19 Dec 2024filed 23 Dec 2024 | Discover Financial Services | SEC FORM 4 Code F | $2.0M11,702 at $169.27 | filing |
| 30 May 2024filed 31 May 2024 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 22 Feb 2024filed 26 Feb 2024 | Discover Financial Services | SEC FORM 4 Code A | —29,324 at $0.00 | filing |
| 22 Feb 2024filed 26 Feb 2024 | Discover Financial Services | SEC FORM 4 Code A | —9,051 at $0.00 | filing |
| 1 Feb 2024filed 5 Feb 2024 | Discover Financial Services | SEC FORM 4 Code A | —21,801 at $0.00 | filing |
| 1 Feb 2024filed 5 Feb 2024 | Discover Financial Services | SEC FORM 4 Code F | $1.3M12,290 at $106.56 | filing |
| 1 Feb 2024filed 5 Feb 2024 | Discover Financial Services | SEC FORM 4 Code A | —21,801 at $0.00 | filing |
| 1 Feb 2024filed 5 Feb 2024 | Discover Financial Services | SEC FORM 4 Code F | $1.3M12,290 at $106.56 | filing |
News
CRISPR Therapeutics Announces Chief Financial Officer TransitionCRSP · manilatimes.net · 19 Oct 2026Where Will CRISPR Therapeutics Stock Be in 2030?CRSP · aol.com · 18 Oct 2026Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.CRSP · aol.com · 18 Oct 2026
0 headlines in the last 90 days name John Greene; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.